Skip to main content

August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights

View Additional ASCO 2019 Coverage

FDA Approvals
Keytruda First PD-1 Inhibitor Approved as First-Line Monotherapy for Patients with Metastatic or Unresectable Head and Neck Cancer
Read More
FDA Approvals
Revlimid Approved for Patients with Follicular Lymphoma or Marginal-Zone Lymphoma
Read More
FDA Approvals
Xpovio Receives FDA Approval for Patients with Relapsed or Refractory Multiple Myeloma
Read More
FDA Approvals
Polivy FDA Approved for Patients with Relapsed or Refractory DLBCL
Read More
Prostate Cancer
Enzalutamide or Apalutamide Added to ADT Improves Outcomes in Hormone-Sensitive Prostate Cancer
Phoebe Starr
Read More
Disparities in Oncology, Oncology
Access to Health Insurance Reduces Disparities in Cancer Care: The Case for the ACA
Phoebe Starr
Read More
Renal-Cell Carcinoma, Oncology
Avelumab plus Axitinib New First-Line Standard of Care in Advanced Renal-Cell Carcinoma
Chase Doyle
Read More
Immunotherapy, Oncology
Overcoming Current Barriers to Using CAR T-Cell Therapy in the Community Setting
Chase Doyle
Read More
Neuroendocrine Tumors, Oncology
Combination Immune Blockade Promising in High-Grade Neuroendocrine Tumors: The DART “Basket” Clinical Trial
Phoebe Starr
Read More
Lung Cancer, Oncology
BLU-667, Selective RET Inhibitor, Demonstrates Antitumor Activity in NSCLC with RET Fusion
Wayne Kuznar
Read More
Page 3 of 3
Results 21 - 30 of 30